Toll-like receptor 9 (TLR9) recognizes microbial DNA containing unmethylated cytosyl guanosyl (CpG) sequences, induces innate immune responses, and facilitates antigen-specific adaptive immunity. Recent studies report that in addition to stimulating innate immunity, TLR9 ligands induce apoptosis of TLR9 expressing cancer cells. To understand the mechanism of TLR9-induced apoptosis, we compared the effects of CpG containing oligodeoxynucleotides (CpG ODN) on a mouse B-cell lymphoma line, CH27, with those on mouse splenic B cells. CpG ODN inhibited constitutive proliferation and induced apoptosis in the CH27 B-cell lymphoma line. In contrast, CpG ODN-treated primary B cells were stimulated to proliferate and were rescued from spontaneous apoptosis. The induction of apoptosis required the ODNs to contain the CpG motif and the expression of TLR9 in lymphoma B cells. A decrease in Bcl-xl expression and an increase in Fas and Fas ligand expression accompanied lymphoma B-cell apoptosis. Treatment with the Fas ligand-neutralizing antibody inhibited CpG ODN-induced apoptosis. CpG ODN triggered a transient NF-kB activation in the B-cell lymphoma cell line, which constitutively expresses a high level of c-Myc, while CpG ODN induced sustained increases in NF-kB activation and c-Myc expression in primary B cells. Furthermore, an NF-kB inhibitor inhibited the proliferation of the CH27 B-cell lymphoma line. Our data suggest that the differential responses of lymphoma and primary B cells to CpG ODN are the result of differences in NF-kB activation. The impaired NF-kB activation in the CpG ODN-treated B-cell lymphoma cell line alters the balance between NF-kB and c-Myc, which induces Fas/Fas ligand-dependent apoptosis.
INTRODUCTION
Toll-like receptors (TLRs) belong to a family of pattern-recognition receptors 1 that recognize pathogen-associated molecular patterns, such as bacterial lipopolysaccharides (LPS) and DNAs. TLRs trigger innate immune responses, which play a crucial role in limiting the early replication and spread of pathogens during infection. TLRs also cause the activation of antigen presenting cells, which leads to the induction of adaptive immune responses that provide long-lasting protection. 2 Toll-like receptor 9 (TLR9) recognizes unmethylated cytosyl guanosyl (CpG) sequences that are present at a higher frequency in the genomes of prokaryotes than that of eukaryotes. 3, 4 TLR9 is primarily expressed by B cells and plasmacytoid dendritic cells (pDCs) in humans. 5 In mice, TLR9 is expressed by macrophages and myeloid dendritic cells (mDCs) in addition to B cells and pDCs. 6 TLR9 binds its ligand in endocytic vesicles and recruits the adaptor protein MyD88, 7 leading to the formation of TLRMyD88-IRAK4-IRAK1-TRAF6 signaling complexes.
8 IRAK1 recruits and phosphorylates tumor necrosis factor receptorassociated factor 6 (TRAF6). 9 TRAF6 activates tumor growth factor b-activated protein kinase 1 (TAK1), 10 which activates IkB kinase complex (IkK) and leads to the activation of nuclear factor (NF)-kB. Treating B cells with CpG oligodeoxynucleotides (ODN) causes the upregulation of several transcription factors, including NF-kB, c-Myc, activating protein 1 (AP-1), and the cAMP-responsive element-binding protein (CREB), 11, 12 resulting in a strong Th-1-biased immune response with secretion of pro-inflammatory cytokines, such as IL-6 and IL-12.
proliferation in culture.
14 This anti-apoptotic effect is attributed to TLR9-induced sustained NF-kB activation and increases in the protein levels of c-Myc and the anti-apoptosis protein Bcl-xl. [14] [15] [16] In contrast to its anti-apoptotic function, signaling through TLRs has also been shown to induce apoptosis. Bacterial lipoproteins, LPS and dsRNA, which signal through TLR2, TLR4 and TLR3, respectively, have been shown to induce apoptosis, especially in prestimulated cells. [17] [18] [19] TLR-mediated apoptosis of prestimulated cells has been proposed as a crucial feedback mechanism that downregulates TLR-induced immune cell activation and prevents overactive inflammatory responses that may lead to autoimmune diseases and other disease pathologies, such as sepsis and airway inflammation. 20 However, the mechanism underlying TLR-induced apoptosis remains to be elucidated.
Recently, studies on the immunological functions of TLR9 discovered the potential use of CpG ODN as a therapeutic agent for cancer and autoimmune diseases. 21 It has been reported that CpG ODN alone or in combination with other therapies, such as chemotherapy and monoclonal antibody (mAb), induced tumor regression of lung and skin malignancies. 21 In murine models of T-cell lymphoma and cervical carcinoma, CpG DNA treatment led to tumor regression as the result of T cell-or NK cell-dependent lysis of tumor cells. 22, 23 B-cell lymphomas are unique in that they can express TLR9 and directly respond to CpG DNA. Recent reports showed that CpG ODN sensitizes B-cell chronic lymphocytic leukemia (B-CLL) cells to apoptotic triggers. 24, 25 These studies suggest that TLR9 ligands have dual effects on TLR9-expressing cancer cells: stimulating anti-cancer immune responses and inducing apoptosis of cancer cells.
To examine the mechanism by which TLR9 induces apoptosis in cancer B cells, we compared the effects of CpG ODN on the CH27 mouse B-cell lymphoma cell line with those on mouse splenic B cells. We showed that CpG ODN induces apoptosis in the B-cell lymphoma line, while stimulating proliferation and inhibiting spontaneous apoptosis of naive splenic B cells in culture. By studying signaling molecules downstream of TLR9, we discovered that CpG ODN treatment induced an aberrant NFkB activation and c-Myc expression, a downregulation of the anti-apoptotic protein Bcl-xl, and an upregulation of Fas and Fas ligand in the B-cell lymphoma line, triggering multiple interrelated mechanisms that lead to apoptosis.
MATERIALS AND METHODS

Cells, oligodeoxynucleotides and reagents
Purified phosphorothioate-modified ODNs were purchased from Integrated DNA Technologies (Coralville, IA, USA). A CpG ODN sequence (1826) that is optimal for activating mouse B cells was used: 59-TCCATGACGTTCCTGACGTT-39. A GpC control ODN was also used: 59-TCCATGAGCTTCCTG-AGCTT-39. Polymyxin B (Sigma, St Louis, MO, USA) was used to eliminate the possibility of LPS contamination in the ODNs. No significant effect of polymyxin B treatment was observed (data not shown).
The mouse B-cell lymphoma line, CH27, was generated and characterized by Haughton et al. 26 and is an H-2 k IgM 1 cell line. CH27 cells were cultured in DMEM, containing 15% fetal bovine serum, and were supplemented as described previously. 27 TLR9-negative CH27 cells were identified by cloning CH27 cells by limiting dilution and screening for clones that lack tlr9 mRNA using reverse transcription polymerase chain reaction (RT-PCR).
Mononuclear cells were isolated from the spleens of BALB/c and C57BL/6 mice (Charles River Laboratories, Inc., Frederick, MD, USA) by Ficoll (Sigma-Aldrich, St Louis, MO, USA) density gradient centrifugation. B cells were isolated by T-cell depletion using anti-Thy 1.2 antibody (BD Bioscience, San Diego, CA, USA) and guinea pig complement (Rockland Immunochemicals Inc., Gilbertsville, PA, USA). The resulting cells were panned to remove monocytes and dendritic cells. All experiments involving animals have been reviewed and proved by the Institution Animal Care and Use Committee at University of Maryland (R-07-41 and R-10-87).
RT-PCR analyses of tlr9 mRNA TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to purify RNA from two CH27 clones and splenic B and T cells as recommended by the manufacturer. cDNA was generated from this RNA using SuperScript II reverse transcriptase (Invitrogen). Tlr9 mRNA levels were assessed by PCR amplification with tlr9 specific primers and Taq DNA polymerase (Invitrogen) and the following cycling conditions: 94 uC for 30 s, 55 uC for 30 s and 68 uC for 1 min for 25 cycles. The b-tubulin gene was amplified as a control using the following cycling conditions: 94 uC for 30 s, 56 uC for 30 s and 68 uC for 1 min for 25 cycles. The primers specific for tlr9 were 59-GCACAGGAGCGGTGAAGGT-39 and 59-GCAGGGGTG-CTCAGTGGAG-39, and the b-tubulin-specific primers are 59-TGGAATCCTGTGG CATCCA-39 and 9-TAACAGTCCGCC-TAGAA GCA-39 (Integrated DNA Technologies).
Cell proliferation assay CH27 B-cell lymphoma (1310 5 cells/ml) or splenic B cells (5310 5 cells/ml) from BALB/c or C57BL/6 mice were treated for 66 h with varying concentrations of CpG ODN, control GpC ODN, Escherichia coli LPS (Sigma-Aldrich), the NF-kB inhibitor 6-amino-4-(4-phenoxyphenylethyl amino)quinazoline, 28, 29 phorbol-12-myristate-13-acetate (PMA), ionomycin, or PMA plus ionomycin (EMD Chemicals, Billerica, MA, USA) in the presence of CpG or GpC ODN (7 mg/ml). [ 3 H]-thymidine (1 mCi; MP Biomedicals, Irvine, CA, USA) was added to each well during the last 18 h of incubation. Cells were harvested, and cell-associated radioactivity was measured using a scintillation counter. Assessing NF-kB translocation into the nucleus by immunofluorescence microscopy Cells (1310 6 /ml) were incubated with 7 mg/ml ODNs at 37 uC for varying lengths of time, washed with DMEM containing 6 mg/ml bovine serum albumin, and adhered to poly-L-lysinecoated slides (Sigma) for 40 min at 4 uC. Cells were fixed and permeabilized with cold methanol and were incubated with the mAb that was specific for the p65 subunit of NF-kB (Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by an incubation with an Alexa Fluor 546-conjugated secondary antibody (Invitrogen). Cells were also incubated with SYTO-Green (Invitrogen) for 20 min to label the nucleus. Cells were fixed, mounted with Gel Mount (Biomeda, Foster City, CA, USA), and analyzed by confocal microscopy (LSM 510 Zeiss). Control experiments where the primary antibody was omitted showed no significant staining. The immunofluorescence data were quantified by counting cells in five random fields from each slide for each time point from three independent experiments. The number of cells showing translocation of the p65 subunit to the nucleus was counted and expressed as a percentage of the total number of cells in the images.
Apoptosis assay
Western blot analysis CH27 cells (2310 6 cells/ml) and splenic B cells (5310 6 cells/ ml) were incubated with medium alone, 10 mg/ml ODNs or 1 mg/ml LPS at 37 uC for varying amounts of time. Cells were harvested and lysed in 1% Nonidet P-40 lysis buffer (20 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1 mM MgCl 2 , 1 mM EGTA, 1 mM Na 3 VO 4 , 50 mM NaF and protease-inhibitor cocktail) at 4 uC. Equal amounts of lysates were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and western blotting. Blots were probed with anti-cleaved caspase-3, anti-Bcl-2, anti-Bcl-xl, anti-Bax (Cell Signaling Technology, Danvers, MA, USA), anti-IkBa (Santa Cruz Biotechnology) or anti-cMyc (Millipore, Bedford, MA, USA) antibodies followed by horseradish peroxidase-conjugated secondary antibodies. The blots were then stripped and reprobed with anti-tubulin antibody (Sigma) and a horseradish peroxidase-conjugated secondary antibody as a loading control.
Statistical analysis
The significance of differences was assessed using Student's ttest for independent population mean values.
RESULTS
CpG ODN inhibits the proliferation of CH27 B-cell lymphoma cells
Previous studies have shown that synthetic oligodeoxynucleotides containing unmethylated CpG motifs (CpG ODNs) inhibit spontaneous apoptosis of splenic B cells, 14 while sensitizing human B-cell chronic lymphocytic leukemia cells to undergo apoptosis. 24, 25 We sought to compare the effects of CpG ODN on the proliferation of a mouse B-cell lymphoma line, CH27, and murine splenic B cells. The CH27 line was established from lymphatic tumors of 2 a 4 b mice that were repeatedly immunized with sheep red blood cells. 30 CH27 cells and splenic B cells from BALB/c and C57BL/6 mice were cultured with varying concentrations of CpG ODN for 66 h, and the rate of cell proliferation was determined using [ 3 H]-thymidine incorporation. An ODN with a GpC motif in place of the CpG motif (GpC ODN) was used as a control. As previously reported, 14 there was a dose-dependent increase in the proliferation of splenic B cells from both BALB/c and C57BL/6 upon treatment with CpG ODN, while the control GpC ODN failed to induce splenic B-cell proliferation (Figure 1a ). In contrast, CH27 cells, which constitutively proliferate in culture, significantly reduced their proliferation rate as the CpG ODN concentration increased ( Figure 1a ). When cultured in 0.5 mg/ml CpG ODN, the proliferation rate of CH27 cells was reduced by 60% ( Figure 1a ). The proliferation rate of CH27 cells did not decrease further at CpG ODN concentrations greater than 0.5 mg/ml. The control GpC ODN did not affect the proliferation of CH27 cells (Figure 1a) . Similarly, when treated with LPS, a TLR4 agonist, the proliferation of CH27 cells was significantly inhibited in a concentration-dependent manner, and at 1 mg/ml LPS, proliferation decreased to approximately 30% of the proliferation level of untreated CH27 cells (Figure 1b) . These results indicate that CpG ODN and LPS inhibit and stimulate the proliferation of CH27 lymphoma and splenic B cells, respectively.
CpG ODN induces apoptosis of CH27 lymphoma B cells
One possible explanation for the growth inhibition of the CH27 B-cell lymphoma line is the induction of apoptosis. To TLRs induce apoptosis in lymphoma B cells N Arunkumar et al test this hypothesis, we evaluated the levels of activated caspase-3, one of the key mediators of apoptosis. Caspase-3 is activated by the cleavage of its inactive zymogen form (35 kDa) into activated p17 and p12 subunits, which is one of the hallmarks of caspase-mediated apoptosis. 31 After treating CH27 and BALB/c splenic B cells with 1 or 10 mg/ml of CpG or control GpC ODN for 24 h, the levels of cleaved caspase-3 were assessed by western blot. CpG ODN but not GpC ODN treatment resulted in increased levels of cleaved caspase-3 in CH27 cells (Figure 2a ). In contrast, cleaved caspase-3 was undetectable in splenic B cells under similar treatments. This indicates that CH27 cells undergo caspase-dependent apoptosis in response to CpG ODN.
We further determined the timing and prevalence of apoptosis in these cell populations by flow cytometry. CH27 and splenic B cells from BALB/c mice were treated with 1 or 10 mg/ ml CpG ODN or control GpC ODN for 24 and 48 h. At the end of the incubation, cells were stained with Alexa Fluor 488-conjugated Annexin V (AnnV) and propidium iodide (PI) and analyzed by flow cytometry. Cells stained with AnnV only (AnnV1 PI2) were considered apoptotic cells, and cells stained with both AnnV and PI (AnnV1 PI1) were considered necrotic cells. 32, 33 CpG ODN treatment increased the percentage of AnnV1 PI2 apoptotic CH27 cells. While less than 20% of GpC ODN-treated cells were apoptotic, CpG ODN increased the percentage of apoptotic CH27 cells to more than 40% at 1 mg/ml and up to 70% at 10 mg/ml after 48 h incubation ( The antiproliferative and pro-apoptotic effects of CpG ODN on the CH27 B-cell lymphoma line are TLR9-dependent To determine whether the inhibition of cell proliferation and induction of apoptosis of CH27 cells by CpG ODN is dependent on TLR9, we compared the effects of CpG ODN on the proliferation and apoptosis of two different CH27 clones: one that expresses TLR9 and one that does not. TLR9 negative clones were isolated by cloning CH27 cells by limiting dilution and screening for TLR9 expression using RT-PCR. As shown in Figure 3a , CH27 clone 1 and mouse splenic B cells expressed significant levels of tlr9 mRNA, but tlr9 mRNA was undetectable in CH27 clone 2 and splenic T cells. In contrast to the antiproliferative and pro-apoptotic effects of CpG ODN on the tlr9-expressing CH27 clone 1, CpG ODN neither altered the proliferation rate ( Figure 3b Figure 5b ; and data not shown). This indicates that CpG ODN differentially regulates the expression levels of the anti-apoptotic protein Bcl-xl in CH27 and splenic B cells, contributing to the different fates of these two types of B cells.
Differential effects of CpG ODN on NF-kB activation in CH27 B and splenic B cells NF-kB is the primary downstream target of TLR9 signaling pathway 11, 16 and is a key regulator of B cell fate. 35 Next, we tested whether CpG ODN treatment affects NF-kB activation in CH27 and splenic B cells by assessing the nuclear translocation of the NF-kB p65 subunit and the degradation of the inhibitory component of NF-kB, IkBa. Nuclear translocation of NF-kB p65 was visualized by immunofluorescence microscopy. CH27 and splenic B cells were treated with CpG ODN (7 mg/ml) or control GpC ODN for varying lengths of time. At each time point, the cells were fixed, permeabilized, and stained with a mAb specific for the p65 subunit of NF-kB and a DNA dye. The basal level of and an increase in apoptosis. To examine the role of NF-kB in the CpG ODN-induced apoptosis of CH27 cells, we assessed the effect of NF-kB activators and an activation inhibitor on CH27 cell proliferation. In B cells, protein kinase C is the primary upstream activator of NF-kB. 36 To activate NF-kB, we treated CH27 cells with varying concentrations of the protein kinase C activators phorbol myristate acetate (PMA), ionomycin, and a combination of the two. To inhibit CpG ODN-induced transient NF-kB activation, CH27 cells were treated with various concentrations of the NF-kB activation inhibitor 6-amino-4-(4-phenoxyphenylethylamino) quinazoline in the presence of CpG or GpC ODN. The protein kinase C activators slightly increased the proliferation rate of CH27 cells (Figure 7a ). The combination treatment of CpG ODN and the NF-kB inhibitor induced a stronger inhibition of CH27 proliferation than CpG ODN alone or NF-kB inhibitor plus GpC ODN (Figure 7b ). This suggests that CpG ODN-induced CH27 cell apoptosis is associated with the inhibition but not the transient activation of NF-kB. 
Differential effects of
DISCUSSION
Recent studies have shown that the binding of ligands to TLR2, 3, 4, 6 and 9 can lead to apoptosis of cancer cells and bacterially infected macrophages. 19, 24, 25, 38, 39 However, the cellular mechanisms underlying the induction of apoptosis remain elusive. By comparing the effects of the TLR9 agonist CpG ODN on a mouse B-cell lymphoma line with those on naive mouse splenic B cells, we found that CpG ODN induced apoptosis in the B-cell lymphoma line CH27, which constitutively expresses Bcl-xl and c-Myc, but promotes the proliferation of splenic B cells. CpG ODN-induced apoptosis of CH27 cells is dependent on the expression of TLR9 and the interaction of Fas and Fas ligand and is associated with aborted NF-kB activation of and a decrease in Bcl-xl expression.
The finding that CpG ODN induces apoptosis of a mouse Bcell lymphoma line, CH27, corroborates recent reports that TLR9 ligands induce apoptosis in B cells from patients with B-CLL. 24, 25 Our study further supports a pro-apoptotic effect of TLR9 ligands on TLR9-expressing tumor cells. The CH27 murine B-cell lymphoma line was generated in mice immunized with sheep red blood cells 30 and expresses CD5 and mIgM specific for phosphocholine, which is similar to the phenotype of B-CLL cells. 26, 40, 41 Surface immunoglobulins (Igs) of most B-CLL cells react to self-antigens, such as DNA, phosphatidylcholine and Igs. 42, 43 Here, we show that CH27 cells constitutively express high levels of Bcl-xl and c-Myc, two genes that are commonly deregulated and translocated to the IgH locus in B-cell cancers, such as human Burkitt's lymphoma. 34, 44, 45 Even though it is rare, c-Myc has also been shown to be constitutively expressed in B-CLL cells. vitro model in understanding the mechanisms underlying the pro-apoptotic function of TLR9 on B-cell cancers. This study provides strong evidence that CpG ODN-induced apoptosis is mediated by TLRs. Only ODN that contain the CpG motif and is known to bind to TLR9, but not ODN that has an inverted CpG motif (GpC), exhibit pro-apoptotic effects. Furthermore, CpG ODN induces apoptosis of TLR9-expressing CH27 cells but had no effect on the proliferation and apoptosis of CH27 cells that do not express TLR9. Introducing TLR9 to TLR9-negative CH27 cells restores their apoptotic response to CpG ODN. In addition, our results show that the TLR4 agonist LPS also can induce apoptosis of CH27 cells, indicating that the pro-apoptosis effect is not limited to TLR9. This is similar to the finding by Gruppi et al. 47 that LPS increases the sensitivity of B cells to Fas/Fas ligand mediated apoptosis. These data suggest that common signaling cascades downstream of TLRs are responsible for the induction of apoptosis of CH27 cells, and the TLR signaling pathways in CH27 cells are likely to be different from those in splenic B cells. Indeed, recent studies have found mutations in MyD88, the key signaling adaptor protein of TLRs, in human cancer B cells. 48, 49 While it remains to be determined whether or not TLR signaling components in CH27 cells are mutated, the induction of CH27 apoptosis by TLR agonists implicates their therapeutic potential in treating TLR-expressing B-cell lymphomas.
To further understand how CpG ODN induces apoptosis of CH27 cells, we assessed the effects of CpG ODN treatment on the levels of cleaved executioner caspase 3, Fas and Fas ligand, and the Bcl-2 family proteins Bcl-2, Bcl-xl and Bax that regulate mitochondrial stability. This study shows that CpG ODN 50 In addition to Bcl-xl, other members of Bcl-2 family, 51 could also play roles in CpG ODN-induced apoptosis of CH27 cells.
NF-kB is a key TLR-activated transcription factor 8 and a primary regulator of c-Myc expression. 52, 53 Other than activating the transcription of c-Myc, NF-kB can induce the transcription of anti-apoptotic genes, such as Bcl-xl, 54 ,55 which promote cell survival. The deficiency of Rel-A/p65, a member of the NF-kB family expressed in B cells, increases cell sensitivity to TNF-mediated apoptosis, 56 indicating a role for NF-kB in suppressing apoptosis in B cells. The c-Myc protein is expressed from immature stages of B-cell development, 57 and its expression level increases upon stimulation. 58 c-Myc has long been known as an inducer of apoptosis. 59, 60 Overexpression of c-Myc induces apoptosis in fibroblasts and myeloid cell lines in the absence of stimuli. 60, 61 c-Myc sensitizes cells to TNF-mediated apoptosis by inhibiting NF-kB activation. 62 The expression of c-Myc is also important for cell proliferation. c-Myc has been found to be constitutively activated Representative results from three independent experiments are shown. *P,0.01 compared to GpC ODN-treated cells. CpG, cytosyl guanosyl; NF, nuclear factor; ODN, oligodeoxynucleotide; PMA, phorbol-12-myristate-13-acetate. or expressed in a number of human B-cell lymphomas via gene translocation, which has been implicated in tumorigenesis. 44, 57 The relative activation and expression levels of NF-kB and cMyc have been shown to be critical for controlling the balance between cell proliferation and apoptosis. 63, 64 c-Myc-induced cell proliferation accompanied by impaired activation of NFkB and insufficient levels of anti-apoptotic signals leads to apoptosis, [65] [66] [67] while overexpression of the p65 subunit of NF-kB rescues cells from c-Myc-dependent cell death. 62 Therefore, cooperation between NF-kB and c-Myc is crucial to cell fate.
Our study shows that CH27 cells constitutively express a high level of c-Myc independent of NF-kB activation and that CpG ODN and LPS induce a transient activation of NF-kB, which contrasts sharply with the steady increase of NF-kB activity in naive splenic B cells. While the mechanism of this transient NF-kB activation is not defined, c-Myc has been shown to induce apoptosis by inhibiting NF-kB activation. 62 Based on the discussion above, impaired NF-kB activation plus a constitutively high level of c-Myc could cause the downregulation of Bcl-xl and the upregulation of Fas and Fas ligand expression in CpG ODN-treated CH27 cells. Our findings that the activation NF-kB using protein kinase C activators increases CH27 cell proliferation and the inhibition NF-kB activation further enhances the inhibitory effect of CpG ODN on CH27 cell proliferation, further supporting the idea that the CH27 cell proliferation is partially dependent on NFkB activation and that CpG ODN-induced apoptosis of CH27 cells is, at least in part, the result of hypoactivation of NF-kB.
Our data clearly show that CpG ODN-induced CH27 cell apoptosis is dependent on Fas and the Fas ligand and is associated with the increase of Fas and Fas ligand surface expression. Both c-Myc and NF-kB are involved in the regulation of Fas and Fas ligand expression. The expression of c-Myc is associated with an increase in Fas and Fas ligand expression. B cell-specific c-myc gene deletion reduces stimulus-induced expression of Fas and the Fas ligand and increases resistance to Fas ligand-induced apoptosis. 68 In contrast, NF-kB appears to suppress Fas-mediated apoptosis. While the regulation of Fas/ Fas ligand expression by NF-kB has not been well studied in B cells, it has been shown that NF-kB activation suppresses Fasmediated apoptosis in T cells and macrophages. 69, 70 These data support our hypothesis that the transient activation of NF-kB and the persistently high c-Myc levels create a situation where c-Myc-induced expression of Fas and the Fas ligand in the absence of sufficient anti-apoptotic signals from NF-kB culminates in apoptosis.
Cellular alterations in apoptosing CH27 cells are very similar to what was previously observed in apoptosing WEHI 231 B cells, a widely used B cell model for apoptosis research. 71 WEHI 231 is a B-cell line that behaves like immature B cells and undergoes apoptosis in response to anti-IgM antibody. 72, 73 The cross-linking of surface IgM causes transient activation and expression of NF-kB and c-Myc, respectively, followed by decreases of both in WEHI cells. 74, 75 However, CpG ODN rescues WEHI cells from anti-IgM antibody-induced apoptosis. 74, 76 This rescue has been linked to the sustained activation of NF-kB and expression of c-Myc induced by CpG ODN, 74 similar to what we observed in CpG ODN-treated splenic B cells. This suggests that apoptosis of both CH27 and WEHI B cells may be mediated by similar downstream signaling cascades, even though apoptosis is induced by different receptors.
Our results suggest that TLR-induced apoptosis of CH27 cells is associated with the imbalanced activation of NF-kB and c-Myc, but our results do not exclude the involvement of other mechanisms. CpG ODN has been shown to cause apoptosis of human B-CLL cells by inducing autocrine IL-10 and IL-10-activated JAK/STAT pathway. 24 CH27 cells are B-1 B cells. Normal B-1 cells increase IL-10 and Fas ligand expression in response to TLR activation. 77 However, the induction of IL-10 autocrine signaling in both normal B cells and B-CLL cells has been shown to be NF-kB-dependent. 24, 78 It is unclear whether the transient activation of NF-kB in CpG ODN-treated CH27 cells is sufficient to induce a significant amount of IL-10. TLRs are known to induce the activation of the MAP kinase JNK. JNK and its downstream transcription factors have been shown to be required for the survival of lymphoma B cells. [79] [80] [81] However, CpG ODN does not appear to have any effect on JNK phosphorylation (data not shown) in CH27 cells. Therefore, JNK may not be a major contributor of CH27 cell apoptosis. Previous studies have shown that anti-IgM antibody-induced apoptosis of WEHI B cells is dependent on an increased production of ceramide. 82, 83 Ceramide, a lipid secondary messenger that induces apoptosis, 84 has been suggested to act upstream of Bcl-xl with protein kinase C in WEHI B cells. 82 Because ceramide has been shown to be involved in apoptosis induced by many stimuli including Fas and Fas ligand interaction, 85 it is expected to contribute to CpG ODN-induced apoptosis as well, potentially through Fas and/ or TLR-induced or lymphoma B-cell intrinsic alterations in ceramide metabolism.
While the molecular mechanism by which CpG ODN induces NF-kB activation via TLRs has been well studied, why TLRs in CH27 cells fail to induce sustained NF-kB activation remains unclear. Such a failure is likely to be associated with high levels of basal signaling activities in cancer B cells, such as the constitutively high expression levels of c-Myc and Bcl-xl in CH27 cells. Because different cancer B cells have different genetic mutations and translocations, they will respond to TLRs differently, and apoptosis will be triggered through different pathways in different cancer cells. Further studies on the responses of different cancer B cells to TLR signaling will increase our understanding of their oncogenic mechanisms and allow us to match treatments with the cancer genotype.
